Oculis (OCS) Short Interest Ratio & Short Volume $17.61 -0.03 (-0.17%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oculis Short Interest DataOculis (OCS) has a short interest of 20,900 shares, representing 0.06% of the float (the number of shares available for trading by the public). This marks a -60.57% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 13,854 shares to cover all short positions.Current Short Interest20,900 sharesPrevious Short Interest53,000 sharesChange Vs. Previous Month-60.57%Dollar Volume Sold Short$373.90 thousandShort Interest Ratio0.9 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares43,662,000 sharesFloat Size34,950,000 sharesShort Percent of Float0.06%Today's Trading Volume7,983 sharesAverage Trading Volume13,854 sharesToday's Volume Vs. Average58% Short Selling Oculis? Sign up to receive the latest short interest report for Oculis and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOCS Short Interest Over TimeOCS Days to Cover Over TimeOCS Percentage of Float Shorted Over Time Oculis Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202520,900 shares $373.90 thousand -60.6%0.1%0.9 $17.89 6/30/202553,000 shares $1.03 million +107.8%0.2%1.7 $19.41 6/15/202525,500 shares $485.01 thousand +17.5%0.1%0.7 $19.02 5/31/202521,700 shares $423.15 thousand +29.9%0.1%0.6 $19.50 5/15/202516,700 shares $305.61 thousand +16.0%0.1%0.4 $18.30 4/30/202514,400 shares $250.56 thousand -36.3%0.0%0.3 $17.40 4/15/202522,600 shares $405.22 thousand -55.4%0.1%0.4 $17.93 3/31/202550,700 shares $964.82 thousand +46.1%0.2%0.7 $19.03 3/15/202534,700 shares $651.32 thousand +38.8%0.1%0.5 $18.77 2/28/202525,000 shares $489.50 thousand -14.1%0.1%0.4 $19.58 Get the Latest News and Ratings for OCS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. 2/15/202529,100 shares $628.27 thousand +127.3%0.1%0.4 $21.59 1/31/202512,800 shares $293.25 thousand -68.6%0.1%0.2 $22.91 1/15/202540,700 shares $902.32 thousand -1.7%0.2%0.6 $22.17 12/31/202441,400 shares $703.80 thousand +88.2%0.2%0.7 $17.00 12/15/202422,000 shares $375.98 thousand -8.7%0.1%0.4 $17.09 11/30/202424,100 shares $386.56 thousand -0.8%0.1%0.5 $16.04 11/15/202424,300 shares $343.60 thousand +54.8%0.1%0.5 $14.14 10/31/202415,700 shares $269.73 thousand -65.2%0.1%0.3 $17.18 10/15/202445,100 shares $649.44 thousand +133.7%0.2%1.2 $14.40 9/30/202419,300 shares $236.62 thousand +6.6%0.1%0.7 $12.26 9/15/202418,100 shares $216.11 thousand -4.2%0.1%0.9 $11.94 8/31/202418,900 shares $226.80 thousand -9.1%0.1%1.1 $12.00 8/15/202420,800 shares $247.52 thousand +20.9%0.1%1.5 $11.90 7/31/202417,200 shares $202.10 thousand -18.5%0.1%1.5 $11.75 7/15/202421,100 shares $245.60 thousand -13.9%0.1%0.8 $11.64 6/30/202424,500 shares $292.78 thousand -7.9%0.1%0.7 $11.95 6/15/202426,600 shares $313.88 thousand No Change0.1%0.7 $11.80 5/31/202426,600 shares $312.82 thousand -42.2%0.1%0.7 $11.76 5/15/202446,000 shares $552.92 thousand +16.8%0.2%1.2 $12.02 4/30/202439,400 shares $514.96 thousand +53.9%0.2%1 $13.07 4/15/202425,600 shares $307.97 thousand -21.0%0.1%0.5 $12.03 3/31/202432,400 shares $390.42 thousand -31.4%0.2%0.9 $12.05 3/15/202447,200 shares $536.66 thousand +20.7%0.2%1.3 $11.37 2/29/202439,100 shares $465.29 thousand +76.1%0.2%1 $11.90 2/15/202422,200 shares $277.50 thousand -41.3%0.1%0.6 $12.50 1/31/202437,800 shares $497.45 thousand +85.3%0.2%1 $13.16 1/15/202420,400 shares $230.11 thousand -2.4%0.1%1 $11.28 12/31/202320,900 shares $234.71 thousand -7.1%0.1%1 $11.23 12/15/202322,500 shares $225 thousand +16.0%0.1%1.2 $10.00 11/30/202319,400 shares $190.61 thousand -18.8%0.1%1.1 $9.83Howard Hughes greatest discovery (Ad)In 1974, the CIA used a fake mining operation to recover a Soviet nuclear sub—and accidentally uncovered something far more valuable: strange rocks on the ocean floor packed with critical metals. Today, those same metals are essential to AI, EVs, quantum computing, and defense. And thanks to recent action from the Trump administration, a $16 trillion treasure could finally be tapped—with one tiny U.S. company at the center of it all.Stream the full exposé and get the name of the company leading the charge. 11/15/202323,900 shares $234.46 thousand -10.2%0.1%1.2 $9.81 10/31/202326,600 shares $260.68 thousand +19.8%0.1%1.3 $9.80 10/15/202322,200 shares $244.20 thousand -28.9%0.1%1.2 $11.00 9/30/202331,200 shares $343.20 thousand -1.9%0.2%1.9 $11.00 9/15/202331,800 shares $394.32 thousand +8.2%0.2%1.8 $12.40 8/31/202329,400 shares $385.14 thousand -42.0%0.1%1.5 $13.10 8/15/202350,700 shares $663.16 thousand +37.0%0.2%2.4 $13.08 7/31/202337,000 shares $458.80 thousand -20.8%0.1%1.9 $12.40 7/15/202346,700 shares $583.75 thousand +48.7%0.2%2.3 $12.50 6/30/202331,400 shares $387.16 thousand +7.9%0.1%1.5 $12.33 6/15/202329,100 shares $356.48 thousand -24.4%0.1%1.3 $12.25 5/31/202338,500 shares $442.75 thousand +9.7%0.2%1.6 $11.50 5/15/202335,100 shares $388.21 thousand No Change0.2%0.7 $11.06 OCS Short Interest - Frequently Asked Questions What is Oculis' current short interest? Short interest is the volume of Oculis shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 20,900 shares of OCS short. 0.06% of Oculis' shares are currently sold short. Learn More on Oculis' current short interest. What is a good short interest ratio for Oculis? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OCS shares currently have a short interest ratio of 1.0. Learn More on Oculis's short interest ratio. What is a good short interest percentage for Oculis? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.06% of Oculis' floating shares are currently sold short. Is Oculis' short interest increasing or decreasing? Oculis saw a drop in short interest in July. As of July 15th, there was short interest totaling 20,900 shares, a drop of 60.6% from the previous total of 53,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Oculis' float size? Oculis currently has issued a total of 43,660,000 shares. Some of Oculis' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Oculis currently has a public float of 34,950,000 shares. How does Oculis' short interest compare to its competitors? 0.06% of Oculis' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oculis: HUTCHMED (China) Limited Sponsored ADR (0.20%), Kymera Therapeutics, Inc. (11.62%), Crinetics Pharmaceuticals, Inc. (13.07%), Immunovant, Inc. (29.97%), Alvotech (1.55%), Organon & Co. (5.68%), NewAmsterdam Pharma Company N.V. (11.06%), Recursion Pharmaceuticals, Inc. (34.95%), Ultragenyx Pharmaceutical Inc. (9.31%), Mirum Pharmaceuticals, Inc. (13.28%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Oculis stock? Short selling OCS is an investing strategy that aims to generate trading profit from Oculis as its price is falling. OCS shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oculis? A short squeeze for Oculis occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OCS, which in turn drives the price of the stock up even further. How often is Oculis' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCS, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies HUTCHMED Short Interest Data Kymera Therapeutics Short Interest Data Crinetics Pharmaceuticals Short Interest Data Immunovant Short Interest Data Alvotech Short Interest Data Organon & Co. Short Interest Data NewAmsterdam Pharma Short Interest Data Recursion Pharmaceuticals Short Interest Data Ultragenyx Pharmaceutical Short Interest Data Mirum Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OCS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.